Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Mesto bisfosfonatov pri zdravljenju bolnikov z rakom
Authors:Borštnar, Simona (Author)
Language:Slovenian
Tipology:1.01 - Original Scientific Article
Organisation:Logo OI - Institute of Oncology
Abstract:Pri bolnikih z rakom in zasevki v kosteh je veliko tveganje za razvoj zapletov v kosteh, kar vodi v razvoj bolečin, patoloških zlomov, kompresije spinalnega kanala, hiperkalcemije in napredujoče nepokretnosti, zaradi česar se slabša kakovost življenja. Bisfosfonati preprečijo, zmanjšajo in odložijo te zaplete. Zaradi uvedbe teh zdravil so zapleti med bolniki z zasevki v kosteh bistveno redkejši. Znanih je tudi čedalje več izsledkov, ki kažejo na vlogo bisfosfonatov v preprečevanju izgube kostne mase med zdravljenjem raka. Danes poznamo vrsto bisfosfonatov, ki se razlikujejo po moči, učinkovitosti, odmerjanju, načinu dajanja in po odobrenih indikacijah za zdravljenje.
Keywords:bisfosfonati, hiperkalcemija, kostni zasevki, kosti, novotvorbe, metastaze
Year of publishing:2008
COBISS_ID:702075 Link is opened in a new window
UDC:616-006
ISSN on article:1408-1741
OceCobissID:65324032 Link is opened in a new window
URN:URN:NBN:SI:doc-IOM7DF6R
Views:2255
Downloads:592
Files:.pdf PDF - Presentation file, download (278,46 KB)
 
Journal:Onkologija
Onkološki inštitut
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:by Authors
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:Undetermined
Title:Biphosphonates in the Treatment of Breast Cancer Patients
Abstract:Cancer patients suffering from bone metastases are at increased risk for skeletal complications, which contributes to increased morbidity and have a negative effect on patients' quality of life. Bisphosphonates prevent, reduce, and delay cancer-related skeletal complications in patients, and have substantially decreased the prevalence of such events since their introduction. In addition, the results of clinical trials investigating the efficacy of bisphosphonates in cancer-treatment bone loss have been recently published. Today, a broad range of bisphosphonates with differences in potency, efficacy, dosing, and administration as well as approved indications is available.

Archive

niGradiv

Back